GlassScriptPhysician profile
Nayyar Syed
NPI 1154411635
$8,177.52
in general payments reported to CMS, 2019-2025
63 companies · $3,544 in 2025
The $3,544 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $150 · 2021: $118 · 2022: $499 · 2023: $1,337 · 2024: $2,200 · 2025: $3,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,903 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,902.99 |
| Education | $178.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $841.10 | 2023-2025 | Enhertu, Imfinzi, Imjudo |
| E.R. Squibb & Sons, L.L.C. | $462.15 | 2020-2025 | Opdivo |
| Glaxosmithkline, LLC. | $429.31 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Pfizer INC. | $423.31 | 2020-2025 | |
| Incyte Corporation | $409.34 | 2022-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $379.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $315.20 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $301.54 | 2019-2025 | Tecvayli, Talvey, Rybrevant |
| Amgen INC. | $254.14 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Regeneron Healthcare Solutions, INC. | $251.70 | 2023-2025 | Libtayo, Lynozyfic |
| Pharmacyclics LLC, An Abbvie Company | $250.03 | 2020-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $223.50 | 2019-2025 | |
| Abbvie INC. | $221.40 | 2024-2025 | |
| Sobi, INC | $193.55 | 2024-2025 | |
| Celgene Corporation | $191.58 | 2022-2025 | Reblozyl, Opdivo, Breyanzi |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $190.64 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $163.31 | 2023-2025 | Tecentriq, Venclexta, Alecensa |
| Karyopharm Therapeutics INC. | $140.57 | 2024-2025 | Xpovio |
| Array Biopharma INC | $137.39 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $135.47 | 2022-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $132.59 | 2024-2025 | Ninlaro, Fruzaqla, Iclusig |
| Stemline Therapeutics INC. | $119.39 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $105.13 | 2024-2025 | Xt Cdx |
| Daiichi Sankyo INC. | $95.74 | 2023-2024 | Enhertu |
| Emd Serono, INC. | $94.17 | 2019-2025 | Bavencio |
| Lilly USA, LLC | $86.02 | 2023-2025 | Jaypirca, Verzenio |
| Aveo Pharmaceuticals, INC. | $85.72 | 2024-2025 | |
| Eisai INC. | $81.13 | 2022-2024 | |
| Caris Mpi, INC. | $79.03 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $78.63 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $74.91 | 2025 | |
| Geron Corporation | $74.79 | 2025 | Rytelo |
| Taiho Oncology, INC. | $73.76 | 2022-2025 | |
| Seagen INC. | $73.23 | 2023 | Tukysa, Padcev |
| Morphosys, US INC. | $73.06 | 2023 | Monjuvi |
| Astellas Pharma US INC | $71.96 | 2023-2024 | Xtandi |
| Ipsen Biopharmaceuticals, INC | $67.83 | 2019-2024 | Onivyde |
| Alnylam Pharmaceuticals INC. | $61.17 | 2024-2025 | Givlaari |
| Genmab U.S., INC. | $58.18 | 2023-2025 | Epkinly, Tivdak |
| Alexion Pharmaceuticals, INC. | $53.54 | 2025 | Ultomiris |
| Beigene USA, INC. | $52.58 | 2023-2024 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $49.35 | 2025 | |
| Springworks Therapeutics, INC. | $48.48 | 2024-2025 | Ogsiveo, Gomekli |
| Adc Therapeutics America, INC. | $44.01 | 2022-2023 | |
| Acrotech Biopharma INC. | $35.91 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $34.47 | 2023-2024 | Clonoseq |
| Puma Biotechnology, INC. | $29.95 | 2025 | |
| Coherus Oncology, INC. | $29.54 | 2023 | |
| Myriad Genetic Laboratories, INC. | $27.16 | 2022 | |
| Menarini Silicon Biosystems, INC. | $24.78 | 2024 | |
| Mirati Therapeutics, INC. | $24.21 | 2024 | Krazati |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Iovance Biotherapeutics, INC. | $22.10 | 2025 | Amtagvi |
| Blueprint Medicines Corporation | $21.63 | 2025 | Ayvakit |
| Beone Medicines USA, INC. | $21.33 | 2025 | Brukinsa |
| Cti Biopharma Corp. | $21.15 | 2023 | Vonjo |
| Legend Biotech USA INC. | $20.99 | 2025 | Carvykti |
| Sun Pharmaceutical Industries INC. | $19.65 | 2025 | |
| Kyowa Kirin, INC. | $19.05 | 2024 | Poteligeo |
| Apellis Pharmaceuticals, INC. | $15.07 | 2024 | Empaveli |
| Rigel Pharmaceuticals, INC. | $14.05 | 2024 | Tavalisse, Rezlidhia |
| Boston Scientific Corporation | $13.50 | 2025 | Lux-Dx Insertable Cardiac Monitor |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayyar Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.